Krystal Biotech (KRYS) Stock Forecast & Price Target

Krystal Biotech is supported by a durable commercial base in VYJUVEK, which generated $389M of revenue in 2025, $366M of gross profit, and $205M of net income, reflecting a 94% gross margin and sustained profitability since 3Q23. Its positive outlook is strengthened by an HSV-1 platform that has already produced an approved product and now offers multiple shots on goal in high-unmet-need rare diseases, including KB113, KB801, KB407, and KB803, with encouraging early proof-of-concept and planned or ongoing late-stage programs. The company’s $1B cash position as of 1Q26, modest R&D burden, and in-house manufacturing support capital efficiency and give it flexibility to fund pipeline expansion while VYJUVEK’s ex-US launches and reimbursement growth extend the growth runway.

Krystal Biotech is exposed to a narrow commercial base, with Vyjuvek carrying the burden of the thesis even as U.S. revenues appear to have plateaued around $88M-$99M since Q4 24 and the company itself expects about $500M in sales this year versus a ~$1B franchise by 2031. The negative view is also driven by recurring treatment friction and durability concerns, since a 2-cc bottle covers only one-third of a patient’s back, new wounds can appear outside treated areas, and prior HSV exposure may require extra testing for neutralizing antibodies. Beyond the lead asset, the pipeline appears highly speculative because the HSV-1 platform faces skepticism on immunogenicity, redosing, inhaled delivery, and limited proof of functional efficacy, while downside risks include clinical execution, regulatory uncertainty, and competition.